GP6 and cardiovascular disorder: This therapeutic direction of research on platelets, as it results from the cited literature, is currently associated with the development of substances (drugs) that mainly modulate their activity, including their action leading to dysregulation of the immune system, by influencing their aggregation or their killing, regulated by their specific receptors, such as the GPVI marker, P-selectin, and FcγRIIa, in cardiovascular diseases.